StockData
Sanofi logo

Sanofi (SNY) KPIs and segments

SNYNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SNYNF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 17, 2026Score 6/30
$47.12−0.41 (-0.86%)

Close on Nov 18, 2026Market cap $114.92BP/E 13.4Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Sanofi · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Sanofi: 106 chỉ số vận hành, trong đó có Biopharma Net Sales, All Newly Launched Medicines & Vaccines và Pharma Launches Cohort, lấy từ 100 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Biopharma Net Sales(€M)8
14,44411,59710,50911,30312,4349,9949,89510,56412,1579,4278,9339,687
Constant Exchange Rate (CER) YoY Growth(%)
14.3%17.8%13.6%13.3%7.0%10.1%9.7%10.3%16.7%10.4%6.5%9.3%
United States(€M)
8,6036,3445,2895,8036,8384,8784,6575,1516,5434,3793,9134,534
Europe(€M)
2,5792,1412,1632,4362,5892,1012,0432,4332,5222,0412,0312,293
Rest of World(€M)
3,2623,1123,0573,0643,0073,0153,1952,9803,0923,0072,9892,860
Net Sales Invoiced in U.S. Dollar (USD Share)(%)
60.4%56.0%51.0%52.4%56.2%49.9%48.0%50.0%52.5%45.5%
Net Sales Invoiced in Euro (EUR Share)(%)
15.3%16.2%17.8%19.2%17.6%18.8%17.7%20.2%18.6%19.5%
Net Sales Invoiced in Chinese Yuan (CNY Share)(%)
5.2%5.7%5.9%4.8%5.4%6.6%6.9%5.1%5.3%6.7%6.6%5.7%
Net Sales Invoiced in Japanese Yen (JPY Share)(%)
2.4%3.0%2.8%3.0%2.7%3.7%3.5%3.4%3.0%3.6%3.7%3.7%
All Newly Launched Medicines & Vaccines ( incl. Beyfortus )(€M)4
2,1761,5301,5171,8161,8059691,1311,668
Pharma Launches Cohort (ALTUVIIIO, Nexviazyme, Rezurock, Xenpozyme, Tzield, Sarclisa, Ayvakit, Qfitlia, Wayrilz)(€M)4
1,3901,3051,1711,1211,046897847827
Dupixent (dupilumab — Immunology Flagship)(€M)4
5,6875,1544,1704,2464,1563,8323,4803,4583,4763,3032,8352,990
Constant Exchange Rate (CER) YoY Growth(%)
34.8%37.6%30.8%32.2%26.2%21.1%20.3%16.0%23.8%29.2%24.9%31.3%
United States(€M)
4,3763,8993,0233,1823,0732,8072,4762,5512,5562,4072,0302,299
Europe(€M)
588583563509504485459431417399371329
Rest of World(€M)
723672584555579540545476503497434362
Kevzara (sarilumab — Immunology)(€M)4
22217712413113113411112610910287105
Influenza & COVID-19 Vaccines (Fluzone High-Dose, Fluad, Flublok)(€M)4
1,25654675751,525141734541,91311573741
Constant Exchange Rate (CER) YoY Growth(%)
-18.8%-61.7%-4.1%31.5%-16.8%26.1%-1.4%-36.8%10.9%20.2%38.1%-4.0%
United States(€M)
911-7232361,03827271781,239115224
Europe(€M)
2432013148356466130480291258
Rest of World(€M)
102413119113168401461947567259
Polio / Pertussis / Hib (PPH) & Booster Vaccines (Pentaxim, Hexaxim, Adacel)(€M)4
823700664551642693668632761711637574
Beyfortus (nirsevimab — RSV Infant Immunization)(€M)4
6311082846867397228484164518182410
Constant Exchange Rate (CER) YoY Growth(%)
-15.4%54.2%2.8%-14.9%19.8%322.2%54.9%106.6%381.8%
United States(€M)
24019462663893654205322114315
Europe(€M)
266780255261778335980795
Rest of World(€M)
125821581658962141861516610
Meningitis, Travel & Endemic Vaccines (MenQuadfi, Rabies, Yellow Fever)(€M)4
476287278227451307302249484297286263
ALTUVIIIO (efanesoctocog alfa — Hemophilia A)(€M)4
40834932532429429125123017215812294
Constant Exchange Rate (CER) YoY Growth(%)
37.8%23.7%42.2%53.0%81.4%91.8%100.0%143.6%278.3%772.2%
United States(€M)
34530527127624723821819816014411592
Europe(€M)
000000000000
Rest of World(€M)
6344544847533332121472
Fabrazyme (agalsidase beta — Fabry Disease)(€M)4
260258265252242263262269253273252242
Nexviazyme / Nexviadyme (avalglucosidase alfa — Pompe Disease)(€M)4
211218208203200192195184163168152131
Ayvakit / Ayvakyt (avapritinib — Systemic Mastocytosis)(€M)3
203190177168137
Sarclisa (isatuximab — Multiple Myeloma)(€M)4
196187167157155140136130114121106103
Cerezyme (imiglucerase — Gaucher Disease)(€M)4
173166186171161173190171164193214133
Alprolix (eftrenonacog alfa — Hemophilia B)(€M)4
172163119149149145160169148141130142
Rezurock (belumosudil — Chronic Graft-versus-Host Disease)(€M)4
1651631331131141321311321311149386
Myozyme / Lumizyme (alglucosidase alfa — Pompe Disease)(€M)4
105108112122122140135132168180191159
Cerdelga (eliglustat — Oral Gaucher Disease)(€M)4
959489838680868781828375
Aldurazyme (laronidase — MPS I)(€M)4
778067637969946967788362
Cablivi (caplacizumab — aTTP Rare Blood Disorder)(€M)4
708568696669677363545958
Jevtana (cabazitaxel — Prostate Cancer)(€M)4
677066606266757773726876
Xenpozyme (olipudase alfa — ASMD)(€M)4
636463615754563841373526
Eloctate (efmoroctocog alfa — Hemophilia A)(€M)4
45845863776570819610586103
Tzield (teplizumab — Stage 2 Type 1 Diabetes Delay)(€M)4
422314161818111815111010
Wayrilz (rilzabrutinib — Immune Thrombocytopenia)(€M)3
19171061
Qfitlia (fitusiran — Hemophilia A & B siRNA Prophylaxis)(€M)3
8754410
Lantus (insulin glargine 100 U/mL)(€M)4
530394419419438426450439430399360276
Constant Exchange Rate (CER) YoY Growth(%)
18.5%-7.0%-0.7%1.1%6.7%11.5%24.4%63.4%33.4%21.0%-15.4%-24.9%
United States(€M)
29316118319921419919619317515811234
Europe(€M)
737373737574758085839283
Rest of World(€M)
164160163147149153179166170158156159
Toujeo (insulin glargine 300 U/mL)(€M)4
430354375332321338354290303313321278
Constant Exchange Rate (CER) YoY Growth(%)
31.2%4.4%10.5%18.6%9.2%10.5%10.0%6.5%18.1%11.0%18.0%11.4%
United States(€M)
1246371595560664654615647
Europe(€M)
130125134128124126122120118122119109
Rest of World(€M)
176166170145142152166124131130146122
Plavix (clopidogrel — Antiplatelet)(€M)4
206216224214223229244211230235238254
Lovenox (enoxaparin sodium — Low-Molecular-Weight Heparin)(€M)4
174180184179196209238231233256262263
Praluent (alirocumab — PCSK9 Inhibitor)(€M)4
156164153132127137130110126126121118
Thymoglobulin (anti-thymocyte globulin — Transplant)(€M)4
134137120124118126122125121129117112
Aprovel / Avapro (irbesartan — Hypertension)(€M)4
10311410410510010211010598108105106
Soliqua / Suliqua (insulin glargine + lixisenatide)(€M)4
938679846266705855565861
Multaq (dronedarone — Atrial Fibrillation)(€M)4
937180767879817772847887
Apidra (insulin glulisine)(€M)4
697070
Synvisc / Synvisc-One (hylan G-F 20 — Viscosupplementation)(€M)4
475835
Industrial Sales (Active Ingredients & Third-Party Manufacturing)(€M)1
891098113696148103124125117157166
Clinical Pipeline Projects (Phase 1 to Registration)1
6161778094828683787877
Potential New Medicines & Vaccines (NMEs / NVEs in Clinical Development)
3636404044404138363839
Global Health Unit (GHU) Active Local Healthcare Partnerships3
8699958783838544
GHU Countries Reached
3735263431292118
GHU Impact Fund Active Investments
98888774
Pipeline Assets Covered by Global Access Plans
13131313121212
Business Gross Profit(€M)1
11,6989,4118,1888,5189,8157,7427,7187,8449,3177,1696,7617,443
Business Gross Margin (% of Net Sales)(%)
81.0%81.2%77.9%75.4%78.9%77.5%78.0%74.3%
Business Operating Income (BOI)(€M)2
5,4303,2912,9672,3414,4452,4612,9022,0784,3272,5212,4172,356
Business Operating Income Margin (% of Net Sales)(%)
37.6%28.4%28.2%20.7%35.7%24.6%29.3%19.7%
Biopharma Segment BOI Margin(%)
37.4%28.2%28.1%20.7%35.7%24.6%29.2%19.3%
Business Net Income(€M)1
4,2552,5012,2641,8563,5471,9402,2121,6423,4111,9511,9081,935
Business Net Income Margin (% of Net Sales)(%)
29.5%21.6%21.5%16.4%28.5%19.4%22.4%15.5%28.1%20.7%21.4%20.0%
Business Earnings per Share (Business EPS)(€)
3.552.091.881.532.911.591.791.31
Free Cash Flow (Non-IFRS)(€M)1
3,2692,6701,0542,6372,9941,4291,0292,3403,187862
Closing Net Debt(€M)
12,20115,51312,90011,00811,0575,10211,2458,77211,48315,1128,5347,793
Property, Plant & Equipment (Net Carrying Value by Asset Class & Geography)(€M)
10,50810,36410,15710,0529,6989,5749,81910,09110,160
Women in Senior Leadership Roles(%)
49.0%48.0%48.0%47.0%47.0%46.0%46.0%
Women in Executive Committee / Executive Roles(%)
44.0%44.0%44.0%44.0%44.0%44.0%43.0%43.0%
Sanofi Strategic U.S.-Listed Biotech Equity Portfolio Value (Form 13F-HR)($M)9
630534336310260176166174
Disclosed U.S.-Listed Biotech Equity Positions
16109891099
Novavax, Inc. Position Value($M)
74.464.856.046.259.743.444.155.3
AnaptysBio, Inc. Position Value($M)
41.355.530.439.925.218.315.310.9
Inhibrx Biosciences, Inc. Position Value($M)
11611077.991.53916.516.217.8
MeiraGTx Holdings plc Position Value($M)
13416510697.010079.582.774.3
Immuneering Corporation Position Value($M)
11.113.514.317.819.0
MapLight Therapeutics, Inc. Position Value($M)
9.2932.718.516.0
Agomab Therapeutics NV Position Value($M)
30.936.129.2
Q32 Bio Inc. Position Value($M)
2.023.111.570.810.480.360.400.84
U.S. Federal Prime Contract Obligations to Sanofi Entities (Monthly / Quarterly / Annual)($M)4
5.92-11.940-2.3143.24.4624.01.0232.83.9318.63.74
Department of Health & Human Services (CDC Vaccines for Children & BARDA)($M)
5.84-12.130.7-2.8442.83.748.640.3032.21.1911.52.96
Department of Veterans Affairs (Pharmaceutical & Vaccine Supply)($M)
00.040.2300000.1002.593.730.02
Department of Defense (Defense Logistics Agency Immunization Supply)($M)
00.118.750.490.150.2515.50.560.080.062.680.61
Department of State($M)
0.07-0.06000.250.340.010.020.5800.140.10
ECB Reference Exchange Rate — U.S. Dollar per Euro (USD / EUR)4
1.151.161.171.161.171.131.051.071.101.081.091.08
Chinese Yuan per Euro (CNY / EUR)
7.767.918.108.258.368.207.667.687.877.807.807.77
Japanese Yen per Euro (JPY / EUR)
183.25185.34183.60179.22172.29163.81160.45162.55163.95167.77161.15159.12
Indian Rupee per Euro (INR / EUR)
109.98110.10107.12103.64102.0097.0591.1490.1892.0189.8290.1689.51
British Pound per Euro (GBP / EUR)
0.860.870.870.880.870.850.840.830.850.850.860.87
U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (NAICS 325412)2
929.30926.20926.00919.30918.70914.80916.50918.50918.10914.00909.00896.40
IFRS Net Sales(€M)2
14,44411,59710,50911,30312,4349,9949,89510,56412,1579,4278,9339,687
Other Revenues (VaxServe Distribution & Royalties)(€M)
7897037359027367417118568207367931,381
Cost of Sales(€M)
3,6323,0173,1383,7563,4122,9932,8893,5763,6632,9972,9693,629
IFRS Gross Profit(€M)
11,6019,2838,1068,4499,7587,7427,7177,8449,3147,1666,7577,439
Research & Development Expenses (IFRS)(€M)
1,8492,2331,7472,2911,8341,9091,8082,2571,8021,6651,6701,815
Selling & General Expenses (IFRS)(€M)
2,3092,4652,3272,7462,2912,2842,2222,6482,2322,1922,1112,466
Amortization of Intangible Assets(€M)1
556552535538461378399450401414484496
IFRS Operating Income(€M)1
4,3491,0472,121-1,0383,6231,4732,2859453,5391,5321,236384
IFRS Net Income Attributable to Equity Holders of Sanofi(€M)1
3,0213431,614-8012,8023,9391,8724992,8151,1131,133-555
IFRS Basic Earnings per Share(€)1
2.520.291.34-0.662.303.241.520.402.250.890.91-0.44
Total Assets(€M)4
130,287129,060128,024126,805129,794124,959131,892132,798126,464
Total Liabilities4
Equity Attributable to Equity Holders of Sanofi(€M)1
72,87969,20772,80871,37673,26370,00874,07477,50774,040
IFRS Net Cash Provided by Operating Activities(€M)2
3,8712,9601,6833,4453,7501,4622,0933,8113,8481,33488

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Sanofi reports consolidated financial and commercial operating results under IFRS in millions of euros (€M) and euros per share (€), with fiscal years ending December 31.
  • Following the separation of Opella (Consumer Healthcare), continuing commercial operations reflect Sanofi's pure-play Biopharma perimeter across Immunology, Vaccines, Rare Diseases, Rare Blood Disorders, Neurology, Oncology, and General Medicines.
  • Constant Exchange Rate (CER) growth rates are published directly by Sanofi and represent the primary basis on which management issues full-year net sales and Business EPS guidance.
  • Where cash flow items are published only on a cumulative year-to-date basis in Form 6-K Appendix 5 (IFRS Operating Cash Flow, PP&E and Software CapEx, Share Repurchases), standalone quarters are derived strictly by subtracting the prior cumulative period within the same reporting basis; standalone quarterly Free Cash Flow is taken directly as reported on Page 1 of each Form 6-K release.
  • Parent-only statutory financial statements of Sanofi S.A. in the French Universal Registration Document are prepared annually under French GAAP for a holding entity and are not comparable to quarterly IFRS consolidated statements; no consolidated-minus-parent subtraction is performed.

Không hiện vì thiếu các kỳ gần đây (10)

  • Opella Consumer Healthcare Segment — reclassified to discontinued operations from 2024 and deconsolidated in 2025 upon sale of a controlling stake (with Sanofi's retained 48.2% interest captured under equity-accounted associates).
  • Commercial Medicine Prescription Counts, Vial Volumes & Treated Patient Counts (e.g., Dupixent '>1.3 million patients') — Sanofi reports commercial medicines strictly in €M net sales and CER %, while patient reach remarks in earnings calls are disclosed only as approximate lower bounds ('more than', 'over') rather than exact continuous series.
  • Cumulative Year-to-Date Patient Reach in Form 6-K Sustainability Appendix (GHU YTD Patients Treated & Access Diabetes YTD Patients) — cumulative YTD unique-patient counts cannot be subtracted across quarters without misstating quarterly active patients; annual de-duplicated GHU NCD patient counts from the CSRD workbook are shown instead.
  • Target Disease Epidemiology Patient Populations (July 2026 IR Epidemiology Update) — point-in-time 2026 disease prevalence and biologic-eligible population estimates without historical multi-year time series.
  • AMF Monthly Share Repurchase Reports — monthly disclosures cover February 2025 through April 2026 only, with no monthly share buyback filings for August–October 2026 after completion of the buyback tranche (quarterly share repurchase cash outflows are included through Q3 2026).
  • SEC Form SD Conflict Minerals Supplier Metrics — narrative compliance disclosures without multi-year comparable numeric smelter/supplier tables.
  • Legacy De-Materialized Products (e.g., Aubagio following 2023 loss of exclusivity) — ceased standalone quarterly table disclosure in 2026 IR sales databooks.
  • Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty › Ayvakit / Ayvakyt (avapritinib — Systemic Mastocytosis) › Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest quarters/months (or 2 latest fiscal years) reported
  • Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty › Wayrilz (rilzabrutinib — Immune Thrombocytopenia) › Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest quarters/months (or 2 latest fiscal years) reported
  • Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty › Qfitlia (fitusiran — Hemophilia A & B siRNA Prophylaxis) › Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest quarters/months (or 2 latest fiscal years) reported

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Sanofi

See a number that looks wrong?